[PRNewswire] Canton Biologics Completes Over 300M Yuan Series C Financing
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Dr. Xiao Shen, founder and CEO of Canton Biologics , said, "I am deeply grateful to the investors in this round for recognizing Canton Biologics' technical expertise and growth potential. From our inception, we've been anchored by values of 'reliability, efficiency, and innovation', and inspired by our vision of empowering future with biotechnology. This financing round will further bolster our progress in biotechnological R&D, strengthen our global presence, perpetually support our partners, and ultimately serve more patients."
이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
-- Led by SDIC Venture Capital
GUANGZHOU, China Sept. 19, 2023 /PRNewswire=연합뉴스/ -- On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding 300 million yuan. This round of financing was led by SDIC Venture Capital, with participation from Guangdong Technology Financial Group, Taipu Life Science Investment, and Chnin Financial. The funds raised in this round will be channeled towards advancing the company's R&D in novel biotechnologies, scaling commercial production capabilities, and expanding its global strategic footprint.
Founded in Guangzhou in 2016, Canton Biologics specializes in the large molecule biopharmaceutical CDMO sector, offering end-to-end services from biopharmaceutical CMC development to commercial production and global clinical supply. The company has achieved outstanding results in high-yield cell line development, complex protein expression capabilities, and robust international manufacturing capabilities. Notably, the company has made significant advancements in the lgM molecule expression platform, expression host cells, high-density cell culture, new formulations, and analytical methodologies. In a testament to their operational efficiency, Canton Biologics achieved a milestone by transitioning from DNA synthesis to CMC production in a mere 7 months, facilitating the swift progression from customers' therapeutics into clinical trials.
Dr. Xiao Shen, founder and CEO of Canton Biologics , said, "I am deeply grateful to the investors in this round for recognizing Canton Biologics' technical expertise and growth potential. From our inception, we've been anchored by values of 'reliability, efficiency, and innovation', and inspired by our vision of empowering future with biotechnology. This financing round will further bolster our progress in biotechnological R&D, strengthen our global presence, perpetually support our partners, and ultimately serve more patients."
The lead investor, SDIC Venture Capital, holds a bullish outlook on Canton Biologics' prospective growth and global expansion, because Canton Biologics is a flagship entity in the large molecule drug CDMO sphere, with extensive expertise and robust technical foundations in areas such as proprietary cell line development, pre-clinical pharmaceutical formulation, large-scale commercial manufacturing, and integrated clinical supply chain management.
The co-investor, Guangdong Technology Financial Group, stated that Canton Biologics' accelerated growth plays a strategic role in enhancing the R&D outsourcing landscape within Guangdong province.
The co-investor, Taipu Life Science Investment, also have a favorable view of Canton Biologics as it boasts a global perspective, a commitment to customer-centric service, a dynamic management cadre, an innovative technical team, and robust capabilities in the industrialization of biotechnologies.
Source: Canton Biologics Co., Ltd.
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 우크라 군소식통 "북한군 2천명, 훈련마치고 러 서부로 이동 중"(종합) | 연합뉴스
- 尹, 우크라 무기 지원에 "북한군 활동에 따라 유연하게 검토"(종합) | 연합뉴스
- 특별감찰관 두고 與계파 세대결…친한·친윤 20∼30명씩 '팽팽' | 연합뉴스
- 의료계 여야의정 협의 추가 참여 지지부진…"전공의 반발 의식" | 연합뉴스
- 부산 미군 55보급창서 화재…4시간 만에 불길 잦아들어(종합2보) | 연합뉴스
- 고위공직자 76명 재산공개…박종석 주쿠웨이트대사 83억8천만원 | 연합뉴스
- 역성장 겨우 피했지만 수출 불안…한은·정부 성장 전망 낮출 듯(종합) | 연합뉴스
- "이번 국감 'D-' 학점…이재명 방탄·김여사 의혹 정쟁국감" | 연합뉴스
- '싸움판' 된 과방위 국감장…野, '위증·불출석' 11명 고발(종합2보) | 연합뉴스
- 이스라엘군 "베이루트의 헤즈볼라 무기 공장 공습" | 연합뉴스